Should We End Obesity? | Neuroscience Shows That Nightly Scents Could Boost Memory and Help Your Productivity | Fentanyl kills thousands every year in America. Will Europe be next? | 6 Tips On How To Write A Cover Letter For An Internship, With Example

View online | Unsubscribe (one-click). For inquiries/unsubscribe issues, Contact Us

� � � � � � Should We End Obesity? - TIME    It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to change not just U.S. medicine, but U.S. culture. Approved in 2017 as a type 2 diabetes medication, Ozempic has largely made its name—and a fortune for its manufacturer, Novo Nordisk—as a weight-loss aid. Novo Nordisk knew early on that diabetes patients often lost weight on the drug, but even company executives couldn’t have guessed how widely it would eventually take off as both an off-label anti-obesity treatment and a vanity-driven status symbol for those simply looking to shed a few pounds. Its runaway success mirrors that of similar medications, including Eli Lilly’s Mounjaro and Wegovy, another Novo Nordisk product and the only one in the trio technically approved for weight loss. Prescriptions for all of them are flying off the pad at an eye-popping rate. Novo Nordisk sold around $14 billion of its various diabetes and obesity drugs in the first half of 2023, and Eli Lilly sold almost $1 billion worth of Mounjaro in a single quarter this year. Prescriptions for these weight-loss meds are up 300% since early 2020, with more than 9 million written in the U.S. in the last three months of 2022 alone, according to health care industry research firm Trilliant Health. Demand is so great that Ozempic, Wegovy, and Mounjaro have all recently gone into shortage, and patients with type 2 diabetes have in some cases struggled to fill their prescriptions as they compete for limited supplies with people looking to slim down; meanwhile, spas, internet suppliers, and compounding pharmacies are all fighting for their piece of the Ozempic pie. Continued here � � � � � � Don't like ads? Go ad-free with TradeBriefs Premium Neuroscience Shows That Nightly Scents Could Boost Memory and Help Your Productivity - Inc.com    College ROI: Higher Education Leads to Significant Earnings Boost, According to a New Study As we age, changes often occur in our sense of smell and cognitive capacity. But new research reveals a simple way to potentially shore up brain power as we get older--by letting scent waft through the air at night.  In a recent study, researchers at the UCI Center for the Neurobiology of Learning and Memory had older adults use an essential oil diffuser by their bedside for just two hours each evening over six months. By exposing participants to a variety of natural scents while they slept, the scientists aimed to tap into the close ties between olfaction and memory. Continued here � � � � � � Fentanyl kills thousands every year in America. Will Europe be next? - The Economist    Many cities in Europe have pockets of such squalor. Yet for all the harm caused to society by drugs commonly scored on the streets of Paris, Berlin or Warsaw, none can match the ravages of fentanyl, a narcotic that has devastated swathes of America. As any recent visitor to downtown San Francisco might attest, the effects of this synthetic opioid, vastly more potent even than heroin, cannot be confined to small areas on the fringes of the city. Drugs of fentanyl’s ilk currently kill around 70,000 Americans a year, more than died in the wars in Vietnam, Iraq and Afghanistan combined. In Europe, that brand of junk never really took off: no more than 200 people are thought to overdose from it every year. Largely as a result of the fentanyl gap, Europe has less than a tenth as many drug deaths as America, despite its bigger population. The ravage that hasn’t happened is a quiet policymaking triumph for Europe. But governments fret that this may not be the case for long. Concern is mounting that the fentanyl onslaught may soon find its way across the Atlantic. Why has fentanyl thus far spared Europe when it caused such devastation in America? Given the drug’s origins—it was synthesised in Belgium in 1959, as a legal painkiller—it might have been expected to be discovered by junkies there first. But it took American no-holds-barred capitalism to help turn it into a phenomenon. From the 1990s on, doctors there prescribed painkillers willy-nilly, incentivised by unscrupulous pharmaceutical firms. By 2015 some 227m prescriptions for opioids were made out every year in America, roughly one for every adult. A cohort of patients hooked on pills soon discovered they were available illicitly when prescriptions ran out. (Mexican cartels were eager to help, often using the requisite chemicals from China.) Europe, by contrast, broadly resisted, in part thanks to universal medical care. Unlike Americans, those with ailments could get the procedures they needed to alleviate pain, instead of turning to painkillers for a quick fix. What addiction there was could be tackled with opioid-substitution treatment schemes. Alas, that may not be enough to keep Europe out of fentanyl’s deadly clutches. The authorities have two concerns. One is around heroin, which Europe’s 1m users of illicit opioids are most often hooked on. Nearly all of the stuff injected or snorted in Europe is derived from poppies grown in Afghanistan. The Taliban, since returning to power, have enforced production cuts of perhaps 95% this year, which is expected to severely curtail the availability of cheap heroin in Europe, come 2024. Facing a dearth of supply, drug gangs are expected either to mix fentanyl into what little heroin they have, to give it extra potency, or to peddle the synthetic drug as a wholesale replacement. A similar shortage of heroin after the last Taliban crackdown in the early 2000s caused fentanyl to take root in Estonia, so far the only part of Europe to have faced a durable outbreak of addiction. This replacement theory is now being tested in Ukraine, where the heroin supply has been disrupted by war but synthetic drugs remain relatively available. Continued here � � � � � � 6 Tips On How To Write A Cover Letter For An Internship, With Example - Forbes    It’s your initial opportunity to gain hands-on experience, improve your skills, and make valuable contributions to your field. While internships can be both paid and unpaid, they are often difficult to get, and writing a well-written cover letter can give you a competitive advantage over the other candidates. By highlighting your interest in the position, qualifications, and suitability for the role, you will improve your chances of being selected. Here are expert tips on how to write a cover letter for an internship. Researching the company before writing your cover letter shows that you are genuinely interested in becoming an intern for them. By studying the company’s mission, values, and culture, it gives you the opportunity to decide whether you want to work with them, and whether the company aligns with your goals and needs. By showing the company you have taken the time to research this, you let them know that you are serious about the position. It is helpful to understand that there will be many people applying to the same internship. Therefore, you should make the effort to stand out by writing an attention-grabbing and engaging first paragraph. Start with a confident and strong opening line about why you are interested in the position. Discuss how you found out about the opportunity, whether through a personal connection, job website, or their company website. Additionally, express your enthusiasm (and not desperation) for wanting to take on the role. Continued here

�

�

�

� � �

You are receiving this mailer as a TradeBriefs subscriber. We fight fake/biased news through human curation & independent editorials. Your support of ads like these makes it possible. Alternatively, get TradeBriefs Premium (ad-free) for only $2/month If you still wish to unsubscribe, you can unsubscribe from all our emails here Our address is 309 Town Center 1, Andheri Kurla Road, Andheri East, Mumbai 400059 - 437931932